Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of EDP-305 with Midazolam, Caffeine, and Rosuvastatin
NCT03187496Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EDP-305 in Nonalcoholic steatohepatitis (NASH), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration up to 17 Days and Area Under the Curve up to 17 Days. Started May 2017; status: completed.
02
Drugs
EDP-305
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03187496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187496.